Macrovipera lebetina venom (MLV)

Macrovipera lebetina venom is a complex biological mixture produced by the Levant viper, consisting of numerous toxic proteins and peptides that exert potent hemotoxic, cytotoxic, and proteolytic effects (PubMed: 25448275). The venom's primary components include snake venom metalloproteinases (SVMPs), serine proteinases, phospholipases A2 (PLA2), and disintegrins, which collectively disrupt the hemostatic system and cause significant local tissue damage (PubMed: 25448275). Envenomation by this species often leads to severe clinical manifestations such as systemic hemorrhage, coagulopathy, and extensive necrosis at the bite site (PubMed: 28603114). While the venom is a dangerous toxin, its individual constituents are valuable in drug discovery; for example, the disintegrin lebetin 2 has been investigated for its potent anti-platelet and cardioprotective properties (PubMed: 15135303). Therapeutic intervention typically involves the administration of specific or polyvalent antivenoms designed to neutralize the venom's enzymatic and non-enzymatic toxins through antibody-mediated binding and clearance (PubMed: 28603114). This neutralization prevents the toxins from interacting with their physiological targets, such as fibrinogen or vascular endothelial cells, thereby halting the progression of envenomation symptoms.

Other names

Levant viper venomBlunt-nosed viper venomVipera lebetina venomKufi viper venom

The primary therapeutic mechanism involves the use of antivenom, which contains polyclonal antibodies or antibody fragments (e.g., F(ab')2) that bind to and neutralize the various toxic components of the venom, such as metalloproteinases and phospholipases, preventing them from interacting with their biological substrates (PubMed: 28603114).